Oncorus IPO

10/1/2020

IPO

$87,000,000

Management says it will use the net proceeds from the IPO as follows:approximately $32.0 million to advance ONCR-177 through our Phase 1 clinical trial, including monotherapy, combination therapy, and expansion cohorts, as well as additional clinical development expenses;approximately $11.5 million to fund preclinical and clinical development expenses for a Synthetic CVA21 product candidate, including candidate nomination and IND-enabling activities;approximately $1.5 million to fund our efforts to develop a product candidate from our second synthetic program based on SVV, through candidate nomination;approximately $2.0 million to fund our efforts to develop ONCR-GBM, an intratumoral product candidate targeting brain cancer that is based on our oHSV platform, through candidate nomination;approximately $18.9 million to fund a portion of the planned buildout of our manufacturing capabilities; andthe remaining proceeds for working capital and general corporate purposes.

Publicly-held

Biopharmaceutical

50 Hampshire St. 401
Cambridge, MA 02139
USA

Oncorus, Inc. (Nasdaq: ONCR) is a biotechnology company developing a next-generation immunotherapy platform of oncolytic viruses to treat several types of cancer, including highly malignant and aggressive cancers.